ANGLE WELCOMES NEW RESEARCH FROM BARTS SUPPORTING POTENTIAL USE OF PARSORTIX TO DETECT AND MONITOR PROSTATE CANCER
November 4, 2016
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, welcomes new research presented during the National Cancer Research Institute (NCRI) annual conference, 6-9 November 2016, which supports the potential use of the Company’s Parsortix cell separation technology. This research details the use of Parsortix as part of a simple blood test, to diagnose and monitor patients with prostate cancer.
Using Parsortix, scientists at the Barts Cancer Institute at Queen Mary University were able to capture a very specific subset of circulating tumour cells (CTCs) from prostate cancer patient blood samples. These CTCs, which cannot be captured by traditional systems, are linked to the spread of the disease and as such could potentially be used, in future, to stage the severity of the prostate cancer and thereafter as a means of monitoring the patient.
Commenting on the research ANGLE’s Founder and Chief Executive, Andrew Newland, said
“This is a significant milestone, which further supports the adoption of Parsortix as a non-invasive alternative to the biopsy of prostate tissue. Biopsy is the current standard of care for men suspected of prostate cancer and yet 75% to 80% of men enduring a biopsy and running the risk of potentially serious complications, do not have prostate cancer. Less than 10% of biopsied patients have aggressive cancer where treatment is recommended. Aside from being non-invasive, Parsortix has the potential to provide the additional staging information to allow physicians to determine which patients require treatment and to provide active monitoring for all prostate cancer patients. We look forward to our continued work with Barts to progress the use of Parsortix in prostate cancer.”
The full text of the announcement from The National Cancer Research Institute (NCRI) is as follows:
TUMOUR CELLS IN BLOOD SAMPLES COULD PREDICT
PROSTATE CANCER SPREAD
RESEARCHERS have found a group of circulating tumour cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research* presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
This is the first time these cell types have been shown to be a promising marker for prostate cancer spread.
In a study of around 80 samples from men with prostate cancer, scientists at the Barts Cancer Institute at Queen Mary University looked for cells that were gaining the ability to migrate and invade through the body.**
Samples with more of these cells were more likely to come from patients whose cancer had spread or was more aggressive.
This means that, in the future, these particular cells could potentially be used as a marker to monitor prostate cancer patients and predict if the disease is going to spread – alongside other monitoring techniques.
There are around 46,500 new cases of prostate cancer each year in the UK, and around 11,000 people die from the disease each year.
Dr Yong-Jie Lu, lead author from QMUL’s Barts Cancer Institute, said:
“Our research shows that the number of these specific cells in a patient’s sample is a good indicator of prostate cancer spreading. By identifying these cells, which have gained the ability to move through the body, we have found a potential new way to monitor the disease.
“If we’re able to replicate these studies in larger groups of people, we may be able to one day predict the risk of someone’s cancer spreading so they can make more informed treatment decisions.”
Dr Chris Parker, Chair of the NCRI’s Prostate Cancer Clinical Studies Group, said:
“There’s a need to develop better tests to identify and monitor men with aggressive prostate cancer. This research has found a promising new marker that could one day make it to the clinic to guide treatment decisions.”
This research was funded by Orchid Cancer Appeal, ANGLE plc and Chinese Scholarship Council. The scientists used a highly innovative cell separation technology Parsortix™, developed by UK company ANGLE plc that is able to capture the circulating tumour cells.